Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Adrafinil | Phenibut | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication) | 250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk) |
| Timing | Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration. | On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours. |
| Cycle Duration | Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring. | STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence. |
| Evidence Level | moderate_human | moderate_human |
Inactive prodrug that is hepatically metabolized to modafinil (via hepatic amidase enzymes) and its inactive acid metabolite modafinilic acid. The active metabolite modafinil then exerts its effects as a DAT inhibitor with downstream orexinergic, histaminergic, and noradrenergic activation. Conversion is incomplete — approximately 33-50% of adrafinil is converted to modafinil, with the remainder forming inactive metabolites. The hepatic first-pass metabolism means onset is delayed (60-90 minutes vs. 30-60 minutes for modafinil).
300-600 mg once daily (for educational context — unregulated prodrug of a prescription medication)
Early morning on an empty stomach for faster hepatic conversion. Onset delayed 60-90 minutes. Avoid afternoon/evening dosing due to long effective duration.
Short-term or intermittent use strongly preferred. Avoid continuous daily use exceeding 3 months without liver function monitoring.
Beta-phenyl derivative of GABA that crosses the blood-brain barrier (unlike GABA itself) due to the addition of a phenyl ring. Acts as a full agonist at GABA-B receptors with 30-68x lower affinity than baclofen, requiring correspondingly higher doses. Also binds to and blocks alpha-2-delta subunit-containing voltage-dependent calcium channels (VDCCs), making it a gabapentinoid similar to gabapentin and pregabalin. At low concentrations, mildly increases dopamine levels in the brain, providing stimulatory and nootropic effects alongside anxiolysis. Weak agonist activity at GABA-A receptors at higher doses.
250-750 mg as needed, maximum 1-2 times per week (for educational context — carries significant dependence risk)
On an empty stomach (food significantly reduces absorption). Onset 2-4 hours. Effects last 4-8 hours with residual effects up to 24 hours. Half-life approximately 5.3 hours.
STRICTLY intermittent use only — maximum 1-2 times per week. NEVER use daily for more than 1 week. Tolerance develops within days, leading to dose escalation and dependence.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →